Influence of Pretreatment with Everolimus and/or Sunitinib on the Acute Hematotoxicity of 177Lu-DOTATATE PRRT

被引：0
|
作者：
Medaer, E. [1 ]
Verslype, C. [1 ]
Van Cutsem, E. [1 ]
Dekervel, J. [1 ]
Clement, P. [1 ]
Nackaerts, K. [1 ]
Gheysens, O. [1 ]
Goffin, K. [1 ]
Jentjens, S. [1 ]
Van Laere, K. [1 ]
Deroose, C. M. [1 ]
机构：
[1] UZ Leuven, Leuven, Belgium
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2019年 / 46卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-217
引用
收藏
页码：S89 / S90
页数：2
相关论文
共 50 条
  • [1] Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of 177Lu-DOTATATE PRRT
    Medaer, Eva
    Verslype, Chris
    Van Cutsem, Eric
    Dekervel, Jeroen
    Clement, Paul M.
    Nackaerts, Kristiaan
    Laenen, Annouschka
    Gheysens, Olivier
    Goffin, Karolien
    Jentjens, Sander
    Van Laere, Koen
    Deroose, Christophe M.
    [J]. ACTA ONCOLOGICA, 2020, 59 (06) : 644 - 651
  • [2] Red Bone Marrow Dosimetry and Haematotoxicity in 177Lu-DOTATATE PRRT
    Tshori, S.
    Glasberg, S.
    Luder, D.
    Krausz, Y.
    Gross, D.
    Schwartz, A.
    Freedman, N.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S775 - S776
  • [3] Optimizing and assessing staff exposure during 177Lu-DOTATATE PRRT
    Ben Reguiga, M.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2015, 56
  • [4] Efficacy of Everolimus Combined with 177Lu-Dotatate in the Treatment of Neuroendocrine Tumors
    Aljubran, Ali
    Badran, Ahmed
    Alrowaily, Mohamed
    Raef, Hussein
    Alzahrani, Ahmed M.
    Almuhaideb, Ahmed
    Almanea, Hadeel
    El-Dali, Abdelmoneim
    Tuli, Mahmoud
    Bazarbashi, Shouki
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2024, 39 (02) : 164 - 168
  • [5] 177Lu-DOTATATE PRRT for Multiple Unusual Metastatic Sites in Neuroendocrine Tumor
    Parghane, Rahul, V
    Basu, Sandip
    [J]. CLINICAL NUCLEAR MEDICINE, 2022, 47 (10) : 874 - 875
  • [6] Liver Steatosis Secondary to PRRT With 177Lu-DOTATATE An Unknown Adverse Effect
    de Lima, Beatriz Matheos
    de Carvalho, Juliana Ribeiro
    Gaspar, Priscilla Romano
    Pujatti, Priscilla Brunelli
    Goncalves, Rinaldo
    [J]. CLINICAL NUCLEAR MEDICINE, 2020, 45 (05) : 374 - 376
  • [7] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; dosimetric findings
    Mok, S.
    Tay, Y.
    Ng, D.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S532 - S532
  • [8] A Phase II Trial of Dose Escalation in 177Lu-DOTATATE PRRT - the Need for Dosimetry
    Sundlov, A.
    Svensson, J.
    Gleisner, K. Sjogreen
    Ljungberg, M.
    Bernhardt, P.
    Hindorf, C.
    Mortensen, N.
    Morin, K.
    Hermann, R.
    Wangberg, B.
    Ohlsson, T.
    Forssell-Aronsson, E.
    Tennvall, J.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S225 - S225
  • [9] Esthesioneuroblastoma (Olfactory Neuroblastoma) Treated With 111In-Octreotide and 177Lu-DOTATATE PRRT
    Makis, William
    McCann, Karey
    McEwan, Alexander J. B.
    [J]. CLINICAL NUCLEAR MEDICINE, 2015, 40 (04) : 317 - 321
  • [10] 90Y-DOTATATE or mixture 90Y/177Lu-DOTATATE - change for the better in PRRT?
    Kunikowska, J.
    Krolicki, L.
    Hubalewska-Dydejczyk, A.
    Sowa-Staszczak, A.
    Mikolajczak, R.
    Pawlak, D.
    Toczylowska, B.
    Kobylecka, M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S182 - S182
12345